Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor.

Taken together, these results demonstrate effective inhibition of parthenolide in NSCLC cell growth by targeting EGFR through downregulation of ERK and AKT expression, which could be promisingly used for patients carrying the EGFR mutation.